Tumor Necrosis Factor Inhibitors for Inflammatory Bowel Disease | New England Journal of
Medicine Skip to main content The New England Journal of Medicine homepage Advanced …

Diseases involving the hepatopancreatobiliary (HPB) system are frequently encountered in
patients with inflammatory bowel disease (IBD). Hepatobiliary manifestations constitute …

Inflammatory bowel diseases (IBD) typically affect patients in their reproductive years. It has
been shown that reproductive issues are of key concern to IBD patients, 1 especially …

Anti-tumor necrosis factor (TNF)-α agents represent an effective treatment for chronic
inflammatory diseases. However, some concerns about their potentially undesirable effects …

Background: In severe refractory sarcoidosis cases not responding to conventional
immunosuppressive treatment, the third-line tumor necrosis factor-alpha (TNF-α) inhibitors …

Extra-intestinal manifestations (EIMs) are reported frequently in patients with inflammatory
bowel disease (IBD) and may be diagnosed before, concurrently or after the diagnosis of …

Tumor necrosis factor-α (TNF-α) inhibitors are known to increase reactivation of concurrent
chronic hepatitis B, but their impact on the hepatitis C virus (HCV) is controversial. Some …

Introduction: Limited data suggest the absence of infliximab in breast milk, thereby implying
the safety of this drug during breast-feeding. We aimed to re-evaluate the presence of …

Materials and Methods: We searched PubMed, Embase, Web of Science, Science Direct,
and the Cochrane Library for eligible studies, and nine articles with 12 groups of data were …

Background Data regarding the prevalence of hepatitis C (HCV) and hepatitis B (HBV) in
inflammatory bowel disease (IBD) patients are conflicting. Methods In all, 315 IBD (252 …